Key Points
- CEO Roger Susi sold 5,000 shares on Dec. 29 at an average price of $97.66 for $488,300, reducing his stake by 0.22% while still owning 2,282,500 shares (about $222.9M).
- iRadimed beat Q3 EPS and revenue estimates and set Q4 2025 guidance of $0.470–0.510 EPS and FY2025 guidance of $1.840–1.880 EPS, and it paid a special $0.50 dividend on Dec. 30 (41.21% payout ratio).
- Analysts rate IRMD a consensus "Moderate Buy" with an average price target of $87.33, and institutional investors own roughly 92.34% of the stock.
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 5,000 shares of the firm's stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $97.66, for a total value of $488,300.00. Following the sale, the chief executive officer owned 2,282,500 shares of the company's stock, valued at $222,908,950. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
iRadimed Price Performance
Shares of IRMD opened at $97.77 on Wednesday. The business's 50-day moving average is $89.63 and its 200-day moving average is $74.89. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of 59.25 and a beta of 1.06. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $98.53.
iRadimed (NASDAQ:IRMD - Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.04. The firm had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Equities research analysts expect that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.
iRadimed Announces Dividend
The business also recently declared a special dividend, which was paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th were paid a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed's dividend payout ratio is 41.21%.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on IRMD. Lake Street Capital reaffirmed a "buy" rating and issued a $100.00 target price on shares of iRadimed in a research report on Monday, November 3rd. Roth Capital set a $90.00 price target on iRadimed in a research note on Friday, October 31st. Zacks Research raised shares of iRadimed to a "hold" rating in a research report on Tuesday, November 4th. Weiss Ratings reiterated a "buy (b-)" rating on shares of iRadimed in a research note on Monday. Finally, Wall Street Zen lowered shares of iRadimed from a "strong-buy" rating to a "buy" rating in a research note on Sunday, October 26th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, iRadimed presently has an average rating of "Moderate Buy" and an average price target of $87.33.
Get Our Latest Stock Report on IRMD
Institutional Investors Weigh In On iRadimed
Several institutional investors and hedge funds have recently added to or reduced their stakes in IRMD. Nuveen LLC bought a new stake in iRadimed during the 1st quarter valued at approximately $1,418,000. American Century Companies Inc. lifted its holdings in shares of iRadimed by 13.8% during the first quarter. American Century Companies Inc. now owns 18,284 shares of the medical equipment provider's stock worth $960,000 after buying an additional 2,213 shares during the last quarter. Voya Investment Management LLC lifted its holdings in shares of iRadimed by 38.2% during the first quarter. Voya Investment Management LLC now owns 11,711 shares of the medical equipment provider's stock worth $615,000 after buying an additional 3,239 shares during the last quarter. Ranger Investment Management L.P. boosted its position in shares of iRadimed by 7.4% in the second quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider's stock valued at $12,845,000 after acquiring an additional 14,730 shares during the period. Finally, Calamos Advisors LLC grew its stake in shares of iRadimed by 98.0% in the second quarter. Calamos Advisors LLC now owns 8,867 shares of the medical equipment provider's stock worth $530,000 after acquiring an additional 4,389 shares during the last quarter. 92.34% of the stock is currently owned by institutional investors and hedge funds.
iRadimed Company Profile
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
